504367746 05/15/2017

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4414438

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
RICHARD HOPKINS	12/29/2016

RECEIVING PARTY DATA

Name:	TESSA THERAPEUTICS PTE. LTD.	
Street Address:	46 KIM YAM ROAD	
Internal Address: #01-14 THE HERENCIA		
City:	SINGAPORE	
State/Country:	SINGAPORE	
Postal Code:	239351	

PROPERTY NUMBERS Total: 1

Property Type	Number		
Application Number:	15594167		

CORRESPONDENCE DATA

Fax Number: (303)268-0065

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 303-268-0066

Email: jpeterson@sbiplaw.com

Correspondent Name: SWANSON & BRATSCHUN, L.L.C. Address Line 1: 8210 SOUTHPARK TERRACE LITTLETON, COLORADO 80120

ATTORNEY DOCKET NUMBER:	0206.221
NAME OF SUBMITTER:	TONY SANNY
SIGNATURE:	/Tony Sanny/
DATE SIGNED:	05/15/2017

Total Attachments: 4

source=0206_221_Assignment_HOPKINS_Tessa_Therapeutics#page1.tif
source=0206_221_Assignment_HOPKINS_Tessa_Therapeutics#page2.tif
source=0206_221_Assignment_HOPKINS_Tessa_Therapeutics#page3.tif
source=0206_221_Assignment_HOPKINS_Tessa_Therapeutics#page4.tif

PATENT 504367746 REEL: 042382 FRAME: 0244

ASSIGNMENT OF INVENTION & PATENT RIGHTS

Parties

- (1) HOPKINS, RICHARD c/o Tessa Therapeutics Pte. Ltd., 46 Kim Yam Road, #01-14 The Herencia, 239351 Singapore, Singapore (the "inventor");
- (2) TESSA THERAPEUTICS PTE. LTD. incorporated and registered in Singapore with UEN: 201120185N and whose office is at 46 Kim Yam Road, #01-14 The Herencia, 239351 Singapore, Singapore (the "Assignee").

Agreed terms

1. Definitions

The definitions in this clause apply in this Assignment.

"Completion Application" means the completion patent application, short particulars of which are set out in Part 2 of the Schedule.

"Invention" means the invention entitled CLINICAL CORRELATES OF IMMUNOTHERAPY EFFICACY, being the subject matter of the Priority Application.

"Patent Application" means the Priority Application, the Completion Application and any future applications linked by one or more priorities to the Priority Application or the Completion Application and all matter contained in such applications and any and all:

- (a) national and regional phase applications of all such applications; and
- (b) divisions, continuations and continuations-in-part of all such applications; and
- (c) patents that may be granted pursuant to any of the aforesaid applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates.

"Priority Application" means the priority patent application, short particulars of which are set out in Part 1 of the Schedule.

2. Assignment

In consideration of the sum of S\$ 1.00 SGD (sufficiency and receipt of which the Inventor expressly acknowledges), the Inventor hereby assigns absolutely to the Assignee all their right, title and interest in all countries, regions and territories of the world in, to and erising from the Invention and, with effect from immediately prior to the filing of each, the Patent Application, including (but not limited to):

- (a) In respect of the Invention and any invention that shall be disclosed in, and all matter that shall be contained in, any of the Patent Applications, the right to file applications, claim priority from such applications, and prosecute and obtain grant of patent or other intellectual property protection in respect of any country, region or territory in the world;
- (b) in respect of each and any Patent Application:

1

PATENT REEL: 042382 FRAME: 0245

- (i) the right to claim priority from and to prosecute and obtain grant of patents; and
- the right to file divisional applications based on the Patent Applications and to prosecute and obtain grant of patent on each and any such divisional application;
- (c) the right to extend to, or register in or in respect of any country, region or territory in the world, each and any of the Patent Applications and to extend to or register in, or in respect of, any country, region or territory in the world any patent or other intellectual property protection granted on any of such applications;
- (d) the absolute entitlement to any patents granted pursuant to any Patent Application; and
- (e) the right to bring, make, oppose or defend claims or actions, appeal proceedings and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of the inventions and the Patent Applications, whether occurring before on or after the date of this Assignment.

3. Further assurance

The Inventor shall, at the Assignee's cost, perform all further acts and things, and execute all further documents, required by law or which the Assignee requests to vest in the Assignee the full benefit of the right, title and interest assigned to the Assignee under this Assignment, including (but not limited to):

- documents required to be signed by or on behalf of the Inventor or the Assignee in the course of any applications which relate to the Invention or to any inventions that shall be disclosed in any of the Patent Applications;
- registration of the Assignee as applicant for, or proprietor of, the Patent Applications; and
- (c) assisting the Assignee in obtaining, defending and enforcing any of the Patent Applications, and assisting with any other proceedings which may be brought by or against the Assignee by any third party or in the resolution of any question concerning the invention, or the Patent Applications or any inventions that shall be disclosed in any of the Patent Applications.

4. Right to amend the Schedule

The Inventor and the Assignee grant the firm of Mewburn Eilis LLP the right to insert in Part 2 of the Schedule to this Assignment any further identification of any existing or future patent applications in any countries, regions or territories of the world, which shall fall within the scope of clause 2 above, or as may be necessary or desirable in order to comply with the rules of a patent office for the recordal of this Assignment.

2

5. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed shall constitute an original of this Assignment, but all the counterparts shall together constitute the same agreement.

6. Governing law and jurisdiction

This Assignment is governed by the laws of Singapore and subject to the exclusive jurisdiction of its courts.

Schedule: The Patent Applications

Part 1: Priority Application[s]

Country	Application No.	Application Date	Title
SG	102015099795	4 December 2015	CLINICAL CORRELATES OF IMMUNOTHERAPY EFFICACY

Part 2: Completion Application(s)

	Country/region	Application No.	Application Date	Title
-				
-	WO	PCT/SG2016/050441	9 September 2016	CLINICAL CORRELATES OF IMMUNOTHERAPY
				EFFICACY

Part 3: Identification of some, but not necessarily all, patent applications falling within the scope of clause 2 of this Assignment

Country/region	Application	Application	Title	Signature for
·	No.	Date		Mewburn Ellis LLP

3

PATENT REEL: 042382 FRAME: 0247 Executed by RICHARD HOPKINS in the

presence of:

SIGNATURE OF INVENTOR

SIGNATURE OF WITNESS

NAME: YOU ITA IDA PURWANTI

ADDRESS: 73 CHOA CHURANG LOOP #06-07, 68 9674

OCCUPATION: SENIOR RESEARCH SCIENTIST

DATE: 29/12/16

Executed by TESSA THERAPEUTICS PTE.

LTD. acting by Miller an

authorised representative, in the presence

of:

SIGNATURE OF AN AUTHORISED

REPRESENTATIVE

SIGNATURE OF WITNESS

NAME: JOVING LOW

ADDRESS: & TOWARDE RAGGERIA \$34-82

OCCUPATION: BLICAGE DATE: 30 Dec 246.

RECORDED: 05/15/2017